Novita Pharmaceuticals Inc, a clinical-stage pharmaceutical company focused on novel cancer drugs through its proprietary fascin inhibitor technology, announced on Thursday additional results from its Phase 2 study evaluating NP-G2-044 in combination with SOC anti-PD-1 therapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

The trial was conducted in patients with advanced solid tumours resistant to prior anti-PD-1 therapy. The oral presentation, titled 'Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy', provides positive data on the therapeutic benefit of NP-G2-044 in combination with immune checkpoint inhibitors (ICIs) to block metastasis and enhance immune response.

An amendment to the study is currently underway to open additional cohorts, which will aim to further evaluate the combination of NP-G2-044 with anti-PD-1 therapy across patient populations and solid tumour subtypes.